The rationale in GBM is that DNMT inhibitors could revert the silencing of tumor suppressor genes and possibly counteract the adaptive methylation changes that confer resistance (Lopez-Bertoni et al., 2015). The gene discussed is DNMT1; the disease is glioblastoma.